Organovo Holdings Inc (NASDAQ:ONVO) showcased new preclinical data demonstrating extended survival and sustained use of its 3D bioprinted human liver tissue when fixed into unhealthy animal models. This data will be showcased at The Liver Meeting 2017 by Vaidehi Joshi of Organovo.
Organovo earlier had put its 3D bioprinted human liver tissue patches into the livers of fit SCID/NOD mice, and is now exhibiting additional data from promising early trials in an established model for “A1AT”. The tissue was made of select non-parenchymal cells and human hepatocytes. Histopathologic and serum assessment of the implanted therapeutic tissue demonstrated engraftment, retention and a major degree of ailment clearing through 125-days post-implantation, a notable jump in duration from the firm’s first preclinical trials, which showed functionality through 28 days.
The data showcase a notable jump in the reported period of implanted human hepatocyte synthetic function, representing sustained presence of important human liver proteins such as A1AT and albumin in the animal bloodstream. Prominently, pathologic assessment of diseased animals getting implanted bioprinted liver tissues indicates an around 75% decline in the pathologic hallmarks of the ailment in treated animals as compared to non-treated control animals in the segment of implant.
Eric David, M.D., J.D., the Chief Strategy Officer and EVP of preclinical development at Organovo, reported that with several patients being cured for inborn errors of metabolism in the U.S., and a yearly cost per patient that surpasses $250,000 for drug therapy alone, the company continues to advance a unique therapeutic offering for direct surgical implantation.
The preclinical data continues to demonstrate robust durability and engraftment of the liver tissue and impressive early evidence of successfully impacting the ailment state in animal models. These data support sustained preclinical development of company’s 3D bio-printed liver tissue for therapeutic application.
In the last trading session, the stock price of Organovo gained more than 2% to close the day at $1.54.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: